Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Queensland Health
Federal Trade Commission

Generated: July 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,716,338

« Back to Dashboard

Summary for Patent: 5,716,338

Title: Dual-chamber type injection cartridge with bypass connection
Abstract:An injection cartridge (1) of the dual-chamber type having a bypass connection (12) between its two chambers (9, 10) which is arranged such that the interior wall of the cartridge is modified in a predetermined area in such a way that the movable wall (11) between the two chambers does not seal completely against the interior wall in said area. The modification of the wall is arranged as a plurality of lands and grooves (12) which have a direction that is inclined in relation to the longitudinal axis of the cartridge barrel.
Inventor(s): Hjertman; Birger (Hasselby, SE), Pavlu; Bohdan (Huddinge, SE)
Assignee: Pharmacia & Upjohn Aktiebolag (Stockholm, SE)
Application Number:08/448,607
Patent Claim Types:
see list of patent claims

No matches for this query

Foreign Priority and PCT Information for Patent: 5,716,338

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9303453Oct 20, 1993
PCT Information
PCT FiledOctober 10, 1994PCT Application Number:PCT/SE94/00949
PCT Publication Date:April 27, 1995PCT Publication Number: WO95/11051

International Patent Family for Patent: 5,716,338

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office0947209► Subscribe
Canada2150253► Subscribe
Germany20022899► Subscribe
Germany69426644► Subscribe
Germany69433044► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Queensland Health
Fish and Richardson
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:

Google Plus